Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial cell–specific LAT1 ablation normalizes tumor vasculature
Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai
Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai
View: Text | PDF
Research Article Angiogenesis Vascular biology

Endothelial cell–specific LAT1 ablation normalizes tumor vasculature

  • Text
  • PDF
Abstract

Some endothelial cells in the tumor vasculature express a system L amino acid transporter, LAT1. To elucidate the role of LAT1 in tumor-related endothelial cells, tumor cells were injected into endothelial cell–specific LAT1 conditional knockout mice (Slc7a5flox/flox; Cdh5-Cre-ERT2), and we found that the shape of the tumor vasculature was normalized and the size and numbers of lung metastasis was reduced. TNF-α–induced expression of VCAM1 and E-selectin at the surface of HUVEC, both of which are responsible for enhanced monocyte attachment and premetastatic niche formation, was reduced in the presence of LAT1 inhibitor, nanvuranlat. Deprivation of tryptophan, a LAT1 substrate, mimicked LAT1 inhibition, which led to activation of MEK1/2-ERK1/2 pathway and subsequent cystathionine γ lyase (CTH) induction. Increased production of hydrogen sulfide (H2S) by CTH was at least partially responsible for tumor vascular normalization, leading to decreased leakiness and enhanced delivery of chemotherapeutic agents to the tumor.

Authors

Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai

×

Figure 3

LAT1 inhibition led to CTH-mediated H2S production, which impaired U937 monocyte adhesion to HUVEC.

Options: View larger image (or click on image) Download as PowerPoint
LAT1 inhibition led to CTH-mediated H2S production, which impaired U937 ...
(A) DNA microarray analysis in HUVEC treated with 100 μM captisol or nanvuranlat for 48 hours. Dark blue dots indicate genes with a greater-than 2-fold up- or downregulation due to nanvuranlat. Red or orange dots showed amino acid metabolic genes or amino acid transporters from GO analysis. (B) qPCR expression analysis of HUVEC cultured in 100 μM captisol (control) or nanvuranlat in the presence or absence of 50 μM PD0325901 or 1 μg/mL rapamycin. (C) qPCR expression analysis of HUVEC cultured in 1, 0.5, 0.2, or 0 × tryptophan restriction media. (D) Quantification of H2S production in HUVEC cultured in EGM2 supplemented with 100 μM captisol or nanvuranlat in the presence or absence of 50 μM PD0325901. HUVEC were loaded with HSip1-DA to visualize H2S production. Bar graph showed mean ± SD (n = 6). (E) H2S production in amino acid starved MCDB131 media. Graph showed mean ± SD (n = 6). (F) Western blot analysis of CTH expression in Ad-control or Ad-miR-CTH–infected HUVEC in the presence or absence of 100 μM captisol or nanvuranlat. β-actin was used as a loading control. Blots provided together were set up in parallel at the same time. (G) qPCR analysis of VCAM1 expression in Ad-control or Ad-miR-CTH–infected HUVEC under 10 ng/mL TNF-α treatment for 4 hours. (H) U937 monocyte adhesion to GYY4137-loaded HUVEC in 100 μM Captisol or nanvuranlat. Bar graph showed mean ± SD (n = 7). (I) Monocyte adhesion to Ad-miR-CTH–infected HUVEC in 100 μM captisol or nanvuranlat. Bar graph showed mean ± SD (n = 7). P values were determined by 1-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05. Scale bars: 100 μm (D and E) and 200 μm (H and I).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts